Susceptibility of Human Immunodeficiency Virus Type 1 to the Maturation Inhibitor Bevirimat Is Modulated by Baseline Polymorphisms in Gag Spacer Peptide 1 | Zendy

Kurt Van Baelen | Zendy; Karl Salzwedel | Zendy; Evelien Rondelez | Zendy; Veerle Van Eygen | Zendy; Stephanie De Vos | Zendy; Ann Verheyen | Zendy; Kim Steegen | Zendy; Yvan Verlinden | Zendy; Graham P. Allaway | Zendy; Lieven Stuyver | Zendy

Open Access

Susceptibility of Human Immunodeficiency Virus Type 1 to the Maturation Inhibitor Bevirimat Is Modulated by Baseline Polymorphisms in Gag Spacer Peptide 1

Author(s) -

Kurt Van Baelen,

Karl Salzwedel,

Evelien Rondelez,

Veerle Van Eygen,

Stephanie De Vos,

Ann Verheyen,

Kim Steegen,

Yvan Verlinden,

Graham P. Allaway,

Lieven Stuyver

Publication year - 2009

Publication title -

antimicrobial agents and chemotherapy

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.07

H-Index - 259

eISSN - 1070-6283

pISSN - 0066-4804

DOI - 10.1128/aac.01650-08

Subject(s) - biology , group specific antigen , genotype , virology , phenotype , mutant , virus , peptide , wild type , mutation , genetics , microbiology and biotechnology , gene , biochemistry

In this study, we evaluated baseline susceptibility to bevirimat (BVM), the first in a new class of antiretroviral agents, maturation inhibitors. We evaluated susceptibility to BVM by completegag genotypic and phenotypic testing of 20 patient-derived human immunodeficiency virus type 1 isolates and 20 site-directed mutants. We found that reduced BVM susceptibility was associated with naturally occurring polymorphisms at positions 6, 7, and 8 in Gag spacer peptide 1.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research